Compass Pathways Plc (CMPS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Compass Pathways Plc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Compass Pathways Plc's ROI in the second quarter of 2026?
Compass Pathways Plc recorded a cumulative net loss of $-394 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -169.92%.
Within the Healthcare sector 618 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3781 to 3936.
In December 2025, Compass Pathways plc (Nasdaq: CMPS), a biotechnology firm focused on mental health solutions, has scheduled participation in two notable investor conferences aimed at enhancing its visibility and attracting potential investors. The company will engage in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 2 at 10:00 AM ET, followed by another discussion at the Piper Sandler 37th Annual Healthcare Conference in New York, New York, on December 3 at 1:30 PM ET. Compass Pathways is primarily recognized for its investigational treatment, COMP360, a synthesized form of psilocybin. The company recently released the results from an open-label Phase 2 study assessing COMP360 s safety and tolerability in 22 patients diagnosed with post-traumatic stress disorder (PTSD). This study, which investigated a single dose of 25 mg of the compound, adds to the growing body of evidence surrounding the clinical applications of psychedelics in mental health treatment. The positive outcomes, disclosed earlier this year, suggest a potentially viable treatment pathway for individuals struggling with PTSD, a condition that has long been challenging to manage.In a bid to broaden the accessibility of its innovative treatments, Compass Pathways has also announced a strategic collaboration with HealthPort, a multi-site community health organization known for its focus on social determinants of health. This partnership aims to inform and facilitate the provision of COMP360 treatment within underserved communities, highlighting the company’s commitment to ensuring that its evidence-based innovations reach diverse patient populations.
as Challenging: Compass Pathways Strives to Innovate Mental Health Care Amid Financial Struggles In a recent press release, London-based biotechnology company Compass Pathways plc has announced the appointment of Lori Englebert as its Chief Commercial Officer. Englebert, who will assume her role on July 8, 2024, will be based in the company s New York City office. This appointment comes as Compass Pathways faces financial challenges, recording a cumulative net loss of $129 million during the 12 months ending in the first quarter of 2024, resulting in a negative return on investment (ROI) of -50.43%. Notably, within the healthcare sector, 339 other companies boasted a higher return on investment. Additionally, Compass Pathways total ranking for return on investment has deteriorated compared to the previous quarter, dropping from 1904 to 2603. These facts present a mixed picture for Compass Pathways. On one hand, the appointment of a new Chief Commercial Officer signals the company s commitment to addressing its financial struggles and ensuring future success. Englebert brings her expertise and leadership to the table, which may contribute to the company s efforts in accelerating access to evidence-based innovation in mental health.
Article for : Compass Pathways Undergoes Leadership Changes as Shares Fall and Losses Mount Compass Pathways, the pioneering mental health care company focused on developing innovative therapies for treatment-resistant depression, announced significant changes within its leadership team. Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia have decided to step down from the Board of Directors, leaving the company in search of a new chair. In the interim, David Norton, an experienced board member and industry veteran, will assume the role of Interim Board Chair. Norton brings with him a wealth of expertise and is expected to provide stable guidance to the company during this transition period. Compass Pathways has initiated a global search to find a permanent replacement for this crucial position.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
